**Core Concept**
Cycling-dependent kinase (CDK) inhibitors are a class of drugs that target the cell cycle progression by inhibiting the activity of CDKs. CDKs are crucial for the progression of cells from one phase to another, and their inhibition can prevent cancer cell proliferation.

**Why the Correct Answer is Right**
CDK inhibitors, such as palbociclib, ribociclib, and abemaciclib, work by binding to CDK4 and CDK6, preventing them from phosphorylating and activating the retinoblastoma protein (Rb). This inhibition leads to a halt in cell cycle progression, specifically in the G1/S phase, preventing cancer cells from proliferating. CRK inhibitors, on the other hand, target the CDK-related kinase (CRK) domain of CDKs.

**Why Each Wrong Option is Incorrect**
**Option A:** This option is incorrect because palbociclib is a known CDK4/6 inhibitor, not a CRK inhibitor.
**Option B:** This option is incorrect because ribociclib is also a CDK4/6 inhibitor, not a CRK inhibitor.
**Option C:** This option is incorrect because abemaciclib is a CDK4/6 inhibitor with some activity against CDK9, but it is not a CRK inhibitor.

**Clinical Pearl / High-Yield Fact**
CDK inhibitors are a class of targeted therapies used in the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) breast cancer.

**Correct Answer: A. Palbociclib**